idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project

idw-News App:


Google Play Store

Share on: 
04/02/2024 11:40

Starving pathogens to death

Dr. Andreas Fischer Presse und Kommunikation
Helmholtz-Zentrum für Infektionsforschung

    Saarbrücken research project on new antibiotics receives ERC Proof of Concept funding

    Due to the progressive spread of antimicrobial resistance, clinically important antibiotics are increasingly losing their effectiveness. New active substances are urgently needed to counteract this development. In order to circumvent existing resistance, new drugs must address previously unused target structures within the pathogens. HIPS scientist Prof. Anna Hirsch has been able to identify one such target and successfully acquired a “Proof of Concept” grant of the European Research Council (ERC) to support the development of novel active substances.

    In order to exert their antimicrobial effect, antibiotics specifically intervene in processes that are crucial for the survival or reproduction of bacteria. These include the synthesis of the bacterial cell wall or the duplication of DNA during cell division. Although a large number of antibiotic products are available on the market, they only address a handful of molecular targets in the respective pathogens. The problem with this is that if a bacterium manages to circumvent a certain mechanism of action, a large number of products potentially lose their effectiveness. In order for new antibiotics to circumvent such resistance, they must address target structures in the pathogens that have not yet been used by any other drug.

    One possible target structure for the development of new active substances is a transport protein named “ECF-T”, which transports vitamins and other cellular components into the bacteria. If the function of ECF-T is disrupted, for example by a drug, the bacteria can no longer gather the necessary vitamins and coenzymes and die. As the transport protein does not occur in human cells, these would not be affected by a potential drug targeting ECF-T. As part of her "NovAnI" project, which was funded by an ERC Starting Grant from February 2018 to January 2023, HIPS department head Anna Hirsch and her team have already discovered some first molecules that bind to ECF-T and reduce its activity. In the new ERC Proof of Concept project, which has now been funded with 150,000 euros, these candidates will be further developed. The aim of the project is to develop active substances that are effective not only in the laboratory but also in animal experiments. The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) is a site of the Helmholtz Centre for Infection Research (HZI) in collaboration with Saarland University.

    Hirsch and her group use digital tools to design the active ingredients, then synthesize them using chemical methods and finally test them in the laboratory. In order for the design of the active substances to be successful, further data must first be collected. "An important part of the project will be to exactly characterize the interaction between our molecules and ECF-T," says Anna Hirsch, Head of the Department of Drug Design and Optimization at HIPS and Professor of Medicinal Chemistry at Saarland University. "We already have an idea of how this might work, but we don't yet know exactly how our candidates bind to ECF-T. The better we understand this interaction, the more precisely we can adapt the drug candidates to their target."

    The funding acquired by Hirsch will run for 18 months. The project entitled "Inhibitors of ECF transporters as novel antibacterial agents" started on April 1, 2024 and marks already the third ERC project awarded to Anna Hirsch.

    Helmholtz Centre for Infection Research:
    Scientists at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and its other sites in Germany are engaged in the study of bacterial and viral infections and the body’s defence mechanisms. They have a profound expertise in natural compound research and its exploitation as a valuable source for novel anti-infectives. As member of the Helmholtz Association and the German Center for Infection Research (DZIF) the HZI performs translational research laying the ground for the development of new treatments and vaccines against infectious diseases.

    Helmholtz Institute for Pharmaceutical Research Saarland:
    The Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Saarbrücken was founded jointly by the HZI and Saarland University in 2009. Scientists at HIPS develop and employ experimental and computational approaches to provide new active substances against infectious diseases, optimise them for use in humans and investigate how they can best be transported to their site of action in the human body. A special focus of the institute is on microbial natural products from soil bacteria and the human microbiota as well as innovative medicinal chemistry-driven approaches.

    Media contact:
    Dr Yannic Nonnenmacher
    PR Manager HIPS
    Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
    Phone: +49 681 98806-4500


    Criteria of this press release:
    Business and commerce, Journalists, Scientists and scholars
    Biology, Chemistry, Medicine
    transregional, national
    Contests / awards, Research projects



    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.


    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).


    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).